Cabozantinib in Advanced Solid Malignancies
Condition: Lung Cancer; Solid Tumor (Not Breast or Prostate Cancers)
MeSH terms: Prostatic Neoplasms; Neoplasms
Intervention: Cabozantinib
Intervention description: 60 mg daily by mouth
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 37.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Metastatic; Refractory; Relapsed

Summary:

      This research study is a Phase II clinical trial. Phase II clinical trials test the
      effectiveness of an investigational drug to learn whether the drug works in treating a
      specific cancer. "Investigational" means that the drug is still being studied and that
      research doctors are trying to find out more about it-such as the safest dose to use, the
      side effects it may cause, and if the drug is effective for treating different types of
      cancer. It also means that the FDA has not approved the drug for this type of cancer, or for
      any use outside of research studies.

      When cancer spreads from the primary tumor, one of the most commons sites it spreads to is
      bone. When cancer spreads to bone there can be significant symptoms such as pain.

      Cabozantinib works by blocking signaling that leads to cancer growth as well as blocking the
      growth of new blood vessels (angiogenesis) that help to feed a tumor. Cabozantinib has been
      studied or is being studied in research studies as a possible treatment for various types of
      cancer, including prostate cancer, brain cancer, thyroid cancer, lung cancer and kidney
      cancer.

      Previous clinical research studies indicate that cabozantinib may also have activity against
      cancer once it has spread to the bones.

      The purpose of this study is to find out if cabozantinib is effective in treating cancer that
      has spread to the bone.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of a solid tumor (not breast or prostate) that is
             metastatic and refractory to or progressed following standard therapies

          -  Has bony metastases

          -  Agree to use medically accepted methods of contraception

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or
             biologic agents within 3 weeks of study entry(6 weeks for nitrosoureas/mitomycin C)

          -  Received radiation to the thoracic cavity/GI tract (within 3 months of study entry),
             to bone or brain metastasis (within 14 days) or to any other site within 28 days

          -  Received prior treatment with small molecule kinase inhibitor or hormonal therapy
             within 14 days/5 half-lives

          -  Received therapy with another investigational agent within past 28 days

          -  Has not recovered from toxicities due to prior therapies

          -  Primary brain tumor

          -  Active brain metastases or epidural disease

          -  Uncontrolled significant intercurrent or recent illness

          -  Allergy or hypersensitivity to components of the study treatment formulation